SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue slipped marginally during the December 2022 quarter. A decline of about Rs. 7991.10 millions was observed as compared to Rs. 8079.80 millions during the corresponding quarter last year.A humble growth in net profit of 19.24% reported in the quarter ended December 2022 to Rs. 1640.30  millions from Rs. 1375.60 millions.Operating profit for the quarter ended December 2022 rose to 2514.00 millions as compared to 2071.60 millions of corresponding quarter ended December 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 7991.10 8079.80 -1.10 24341.80 24255.90 0.35 32175.10 29204.70 10.17
Other Income 236.00 105.00 124.76 735.50 572.80 28.40 762.20 1101.90 -30.83
PBIDT 2514.00 2071.60 21.36 7062.00 6396.80 10.40 8320.50 7079.60 17.53
Interest 0.90 5.80 -84.48 11.60 17.20 -32.56 19.90 35.30 -43.63
PBDT 2399.40 1886.60 27.18 6936.70 6200.40 11.88 8416.40 5318.30 58.25
Depreciation 164.10 178.70 -8.17 485.90 528.40 -8.04 681.90 786.00 -13.24
PBT 2235.30 1707.90 30.88 6450.80 5672.00 13.73 7734.50 4532.30 70.65
TAX 595.00 332.30 79.06 1718.60 1354.80 26.85 3968.70 1665.40 138.30
Deferred Tax -95.10 -57.10 66.55 -176.10 -129.70 35.77 -105.00 78.70 -233.42
PAT 1640.30 1375.60 19.24 4732.20 4317.20 9.61 3765.80 2866.90 31.35
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 31.46 25.64 22.70 29.01 26.37 10.01 25.86 24.24 6.68

Glaxosmithkline Phar Share Price

2432.10 -19.70 (-0.80%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×